Compare ADSE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADSE | LBRX |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | Ireland | United States |
| Employees | 302 | 27 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.5M | 958.7M |
| IPO Year | N/A | N/A |
| Metric | ADSE | LBRX |
|---|---|---|
| Price | $12.46 | $33.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | 9.3K | ★ 323.7K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $549.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.89 | $13.40 |
| 52 Week High | $13.50 | $34.00 |
| Indicator | ADSE | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 68.82 |
| Support Level | $11.20 | $26.75 |
| Resistance Level | $13.50 | $33.47 |
| Average True Range (ATR) | 0.69 | 1.79 |
| MACD | 0.14 | 0.40 |
| Stochastic Oscillator | 88.93 | 91.40 |
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.